IGG anti-β2-glycoprotein I antibodies in adult patients with systemic lupus erythematosus: Prevalence and diagnostic value for the antiphospholipid syndrome

Journal of Rheumatology

Volumn 27, Issue 6, 2000, Pages 1437-1443

  Tubach, Florence ^a   Hayem, Gilles ^a   Marchand, Jean Luc ^a   Weber, Marcel ^a   Palazzo, Elisabeth ^a   De Bandt, Michel ^a   Roux, Sophie ^a   Kahn, Marcel Francis ^a   Meyer, Olivier ^a  

^a BICHAT HOSPITAL   (France)

Author keywords

Anti 2 glycoprotein I antibody; Anticardiolipin antibody; Antiphospholipid syndrome; Lupus anticoagulant

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; BETA2 GLYCOPROTEIN 1; BETA2 GLYCOPROTEIN 1 ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN G ANTIBODY; LOW MOLECULAR WEIGHT HEPARIN; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CARDIOLIPIN ANTIBODY; GLYCOPROTEIN; IMMUNOGLOBULIN G; LUPUS ANTICOAGULANT;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; BLOOD; CHILD; EPIDEMIOLOGY; IMMUNOLOGY; MIDDLE AGED; PREDICTION AND FORECASTING; RISK FACTOR;

ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTICARDIOLIPIN; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; CHILD; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULIN G; LUPUS COAGULATION INHIBITOR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; THROMBOSIS;

EID: 0033625356     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. 2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 1990;87:4120-4.
2. Galli M, Comfurius P, Maassen C, et al. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;1:1544-7.
3. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 1990;2:177-8.
4. 2, glycoprotein I clearly differentiates anticardiolipin antibodies from antiphospholipid syndrome and syphilis. Thromb Haemost 1996;75:717-20.
5. Roubey RAS. Immunology of the antiphospholipid antibody syndrome. Arthritis Rheum 1996;39:1444-54.
6. 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol 1995;22:1899-906.
7. 2 glycoprotein-I binding antibodies are associated with a history of thromboembolic complications in patients with SLE and primary antiphospholipid syndrome. Br J Rheumatol 1995;34:1031-6.
8. 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus. Arthritis Rheum 1996;39:1466-74.
9. 2-glycoprotein I and a conventional anticardiolipin immunoassay. Arthritis Rheum 1996;39:1606-7.
10. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
11. Alarcon-Segovia D, Pérez-Vazquez ME, Villa AR, Drenkard C, Cabiedes J. Preliminary classification criteria for the antiphospholipid syndrome with systemic lupus erythematosus. Semin Arthritis Rheum 1992;21:275-86.
12. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
13. Vitali C, Bencivelli W, Iseberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. Clin Exp Rheumatol 1992;10:541-7.
14. Swaak AJG, Groenwold J, Aarden LA, Statius von Eps LW, Feltkamp EW. Prognosis value of anti-dsDNA in SLE. Ann Rheum Dis 1982;41:388-95.
15. Swaak AJG, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-DNA in systemic lupus erythematosus. Ann Rheum Dis 1986;45:359-66.
16. Ter Borg EJ, Horst G, Hummel EJ, Limburg PC, Kallenberg CGM. Measurement of increases in anti-double-strarided DNA antibody levels as a predictor of disease exacerbation in systemic lupus erythematosus. A long term prospective study. Arthritis Rheum 1990;33:634-43.
17. Brandt JT, Triplett DA. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995;74:1185-90.
18. Worrall JG, Snaith ML, Batchelor JR, Isenberg DA. SLE: a rheumatologic view. Analysis of the clinical features, serology, and immunogenetics of 100 SLE patients during long-term follow-up. QJ Med 1990;74:319-30.
19. Sebastiani GD, Passiu G, Galeazzi M, Porzio F, Carcassi U. Prevalence and clinical associations of anticardiolipin antibodies in systemic lupus: a prospective study. Clin Rheumatol 1991;10:289-93.
20. Cooper RC, Klemp P, Stipp CJ, Brink S. The relationship of anticardiolipin antibodies to disease activity in systemic lupus erythematosus. Br J Rheumatol 1989;28:379-82.
21. Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Fall in antiphospholipid antibody at time of thromboocclusive episodes in systemic lupus erythematosus. J Rheumatol 1989;16:614-7.
22. Derksen RHWM, Biesma D, Bouma BN, Gmeling Meyling FHJ, Kater L. Discordant effects of prednisone on anticardiolipin antibodies and the lupus anticoagulant. Arthritis Rheum 1986;29:1295-6.
23. Miret C, Cervera R. Reverter JC, et al. Antiphospholipid syndrome without antiphospholipid antibodies at the time of the thrombotic events: transient "seronegative" antiphospholipid syndrome? Clin Exp Rheumatol 1997;15:541-4.
24. 2-glycoprotein-I and anticardiolipin antibodies during thrombosis in systemic lupus erythematosus patients. Am J Med 1999;106:417-23.
25. Perez-Vazques M, Villa AR, Drenkard C, Cabiedes J, Alarcon-Segovia D. Influence of disease duration, continued follow up and further antiphospholipid testing on the frequency and classification category of antiphospholipid syndrome in a cohort of patients with systemic lupus erythematosus. J Rheumatol 1993;20:437-42.
26. Meyer O, Piette JC, Bourgeois P, et al. Antiphospholipid antibodies: a disease marker in 25 patients with antinuclear antibody negative systemic lupus erythematosus (SLE). Comparison with a group of 91 patients with antinuclear antibody positive SLE. J Rheumatol 1987;14:502-6.
27. Out HJ, van Vliet M, de Groot PG, Derksen RHWM. Prospective study of fluctuations of lupus anticoagulant activity and anticardiolipin antibody titer in patients with systemic lupus erythematosus. Ann Rheum Dis 1992;31:353-7.
28. 2-glycoprotein I antibodies in systemic lupus erythematosus. Lupus 1995;4:472-6.
29. 2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome. J Rheumatol 1998;25:675-80.
30. 2-glycoprotein I antibodies with lupus-type circulating anticoagulant and thrombosis in systemic lupus erythematosus. Am J Med 1992;93:181-6.
31. 2-glycoprotein I in anticardiolipin negative patients [letter]. J Rheumatol 1998;25:1442.
32. 2-glycoprotein I in the antiphospholipid syndrome: prevalence and isotype distribution. Br J Rheumatol 1996;35:523-8.
33. 2glycoprotein 1. anti-prothrombin and anticardiolipin antibodies in a longitudinal study of patients with systemic lupus erythematosus and the antiphospholipid syndrome. Br J Rheumatol 1998;37:1089-94.
34. 2-glycoprolein I in patients with antiphospholipid syndrome. Br J Rheumatol 1996;35:1239-43.
35. 2-glycoprotein I. antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis. J Rheumatol 1997;24:1710-5.
36. 2-glycoprotein I in systemic lupus erythematosus and primary antiphospholipid antibody syndrome: clinical correlations in comparison with other antiphospholipid antibody tests. J Rheumatol 1998;25:667-74.
37. Abu-Shakra M, Gladman DD, Urowitz MB. Anticardiolipin antibodies in systemic lupus erythematosus: clinical and laboratory correlations. Am J Med 1995;99:624-8.
38. Horbach DA, Oort EV. Donders RCJM, Derksen RHWM, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus. Comparison between different assays for the detection of antiphospholipid antibodies. Thromb Haemost 1996;76:916-24.
39. Petri M. Thrombosis and systemic erythematosus: the Hopkins Lupus Cohort perspective. Scand J Rheumatol 1996;25:191-3.
40. Bertolaccini ML, Atsumi T. Khamashta MA, Amengual O, Hughes GRV. Autoantibodies to human prothrombin and clinical manifestations in 207 patients with systemic lupus erythematosus. J Rheumatol 1998;25:1104-8.
41. Bertolaccini ML, Roch B, Amengual O, Atsumi T, Khamashta MA, Hughes GRV. Multiple antiphospholipid tests do not increase the diagnostic yield in antiphospholipid syndrome. BrJ Rheumatol 1998;37:1229-32.
42. Shah NM, Khamashta MA, Atsumi T, Hughes GRV. Outcome of patients with anticardiolipin antibodies: a 10 year follow up of 52 patients. Lupus 1998;7:3-6.